SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-22-273891
Filing Date
2022-10-31
Accepted
2022-10-31 16:02:52
Documents
5
Group Members
ASTELLAS PHARMA INC.ASTELLAS US HOLDING, INC.

Document Format Files

Seq Description Document Type Size
1 SC 13D d404396dsc13d.htm SC 13D 143247
2 EXHIBIT 1 d404396dex991.htm EX-99.1 6866
3 EXHIBIT 2 d404396dex992.htm EX-99.2 7018
4 EXHIBIT 3 d404396dex993.htm EX-99.3 7022
5 EXHIBIT 4 d404396dex994.htm EX-99.4 6657
  Complete submission text file 0001193125-22-273891.txt   172515
Mailing Address 600 CALIFORNIA ST., 17TH FLOOR SAN FRANCISCO CA 94108
Business Address 600 CALIFORNIA ST., 17TH FLOOR SAN FRANCISCO CA 94108 415-638-6556
Audentes Therapeutics, Inc. (Filed by) CIK: 0001628738 (see all company filings)

IRS No.: 461606174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Subject) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91724 | Film No.: 221345960
SIC: 2836 Biological Products, (No Diagnostic Substances)